This randomized clinical trial examines the effect of oral methylprednisolone on the risk of major kidney outcomes, including 40% decline in eGFR, kidney failure (dialysis, transplant), or death due to kidney disease, and adverse effects in individuals with IgA nephropathy and proteinuria.
